Comparison of the action of associated antigens and associated inactivated cells of c. Albicans and c. Tropicalis fungi

M. V. Rybalkin, N. I. Filimonova, L. S. Strelnikov


Many researchers believe that the use of drugs that can stimulate protective immune responses against candidal infections, i.e. immunobiological drugs stimulating the protective function, is promising in the fight against candidiasis. The aim of this work was to compare protective and therapeutic properties of the associated antigens and the associated inactivated cells of C. albicans and C. tropicalis fungi. The protective and therapeutic effects of the associated inactivated suspension of C. albicans and C. tropicalis fungi with the concentration of 10 + 10 (mln.c/ml) and the associated antigens of C. albicans fungi with the protein concentration of 3 mg/ml, and C. tropicalis with the protein concentration of 5 mg/ml in the ratio of 1:1 were compared. The research was carried out in healthy two month white mice weighing 18-22 g; there were six animals in the control and experimental groups each. As the result of the studies, it has been found that the use of the combined antigens of C. albicans and C. tropicalis provides 100% protective and therapeutic effects in mice. The inactivated suspension of C. albicans and C. tropicalis fungi provides 84% protective and therapeutic effect in mice for 3 months after intramuscular injection of 0.2 ml. In 16% of animals treated with the inactivated suspension of fungi the signs of a mild disease have been revealed. In future it is planned to substantiate experimentally the type and concentration of excipients such as preservatives, stabilizers and adjuvants in the composition of the solution of the associated antigens of C. albicans and C. tropicalis fungal cells.


candidiasis; antigen; vaccine; immunity; therapy

Full Text:



Голубка О.В. // Annals of Mechnikov Institute. – 2011. – №2. – С. 51-59.

Жукова Н.В., Кривошеева И.М. // Кримський терапевт. журн. – 2013. – №2. – С. 99-104.

Carvalho A., Cunha C., Iannitti R.G. et al. // Front. Microbiol. – 2012. – Vol. 3. – P. 1-9.

Cassone A. // Lancet Infect. Dis. – 2008. – Vol. 8. – P. 114-124.

D’Argenio D.A., Wilson C.B. // Immunity. – 2010. – Vol. 33, №4. –P. 437-440.

Grover A., Bhandari B.S., Rai N., Lakhera P.C. // Biotechnol. International. – 2010. – Vol. 3, №1. – P. 4-17.

Han Y., Rhew K.Y. // Arch. Pharm. Res. – 2012. – №35. – P. 2021-2027.

LeibundGut-Landman S., Wutrich M., Hohl T. // Curr. Opin. Immunol. – 2012. – Vol. 24. – P. 1-10.

Nabel G.J. // N. Eng. J. Med. – 2013. – Vol. 6, №368. –Р. 551-60.

Petrov P.V., Khaitov R.M. Immunogens and New Generation Vaccine. – M.: GEOSTAR-Medicine, 2011. – 608 p.

Skibinski A.G.D., Baudner C.B., Manmohan S. et al. // Glob. Infect. Dis. – 2011. – Vol. 3, №1. –P. 63-72.

GOST Style Citations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)